|
11 May 2025 08:00 hrs |
The new face of diabetes |
|
11 May 2025 18:30 hrs |
The genetics of obesity: Can an old dog teach us new tricks |
|
12 May 2025 08:00 hrs |
Thyroid Cancer Across the Lifespan: Similar yet Different |
|
12 May 2025 12:20 hrs |
Adverse effects of endocrine disrupting chemicals though lifecourse |
|
12 May 2025 18:35 hrs |
Crosstalk between pituitary and adrenal gland over life time in Cushing’s syndrome 100 years after Minni G |
|
13 May 2025 08:30 hrs |
Kisspeptin and neurokinin B – vital roles in puberty, fertility and menopause |
|
13 May 2025 17:10 hrs |
The potential of rejuvenating medicine |
Our Plenary speakers:
Chantal Matthieu, Professor of Medicine at the Katholieke Universiteit and Chair of Endocrinology at the University Hospital Gasthuisberg Leuven, Belgium
Chantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. Her basic research work focuses on pathogenesis and prevention of type 1 diabetes. Prof. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes have made her a speaker in international fora. Prof. Mathieu coordinates the European clinical trial network for interventions in type 1 diabetes ‘INNODIA’ and the European project ‘EDENT1FI’ on screening for type 1 diabetes. Prof. Mathieu is president of EASD and vice-president of the European Diabetes Forum.
Giles Yeo, MBE is an American British biologist. He is the professor of molecular neuroendocrinology at the Medical Research Council Metabolic Diseases Unit and scientific director of the Genomics/Transcriptomics Core at the University of Cambridge. He was born in London, UK and and previously lived in Singapore, San Francisco, and since 1994 has been based in Cambridge, UK. In 1994 he graduated from University of California, Berkeley (Molecular and Cell Biology) and in 1997 he completed a PhD study at University of Cambridge (Molecular genetics). His focus is on the study of obesity, brain control of body weight and genetic influences on appetitive behaviour.
Steven Waguespack is a Professor of internal medicine and peadiatrics at the University of Texas MD Anderson Cancer Center in Houston. A native of Louisiana, Dr. Waguespack graduated summa cum laude from Loyola University in New Orleans, where he also participated in the presidential scholars honour programme. He graduated with honours, including junior induction into the Alpha Omega Alpha Honor Medical Society, from The University of Texas Medical School at Houston (now known as the John P. and Kathrine G. McGovern Medical School). Dr. Waguespack completed training in internal medicine/peadiatrics followed by a combined adult and peadiatric endocrinology fellowship at the Indiana University Medical Center in Indianapolis. He maintains board certification in both subspecialties. Consistently recognized as one of “America’s Top Doctors for Cancer” in endocrinology, his major clinical and research interests are thyroid cancer, pituitary tumors, and hereditary syndromes of endocrine neoplasia. At MD Anderson, where he has been on faculty since 2002, Dr. Waguespack enjoys providing endocrine care to patients of all ages.
Tina Kold Jensen is Professor in environmental epidemiology and has studied adverse effects of exposure to endocrine disrupting chemicals and impact on both fetuses, children and adults. She is the research leader in the Odense Child Cohort, in which more than 100 articles in peer reviewed journals have been published and more than 60 mill DK from external grants have been obtained. She is a member of expert committees in The Danish National Board of Health and The Danish Environmental Agency addressing the adverse health effects of PFAS exposure and knowledge gaps in PFAS and in WHO expert group to evaluate PFAS. In addition, she holds an ERC advanced grant addressing adverse health effects of PFAS exposure.
Martin Reincke is Professor of Endocrinology and Chairman of Medicine at the Ludwig-Maximilians University in Munich. His institution is part of the Klinikum of the LMU, one of the leading institutions in German academic medicine. Reincke’s research focus are the pituitary and adrenal gland, with a focus on primary aldosteronism and Cushing’s syndrome. Reincke is heading a research team specifically exploring the prevalence and relevance of mineralocorticoid and glucocorticoid excess in resistant hypertension on the epidemiological, clinical, genetic and molecular level. Reincke is a member of many national and international societies, including the Endocrine Society, European Society of Endocrinology and European Network of the study of adrenal tumors. He has served in the Executive Board of the German Endocrine Society and European Society of Endocrinology, is on the editorial board of several international journals, has served as teaching dean of the faculty from 2006-2012, and as president of the German Endocrine Society (2014-2017). Prof. Reincke won the prestigious European Research Council Advanced Grant Award (2.5 Mio €) in 2016. He was president of the European Society of Endocrinology 2021-2023 and is currently president of the European Hormone Foundation.
Waljit Dhillo FMedSci is a Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Senior Investigator. He holds the following leadership roles:
(i) Dean of the NIHR Academy.
(ii) NIHR Scientific Director for Research Capacity and Capabilities
(iii) Head of Division of Diabetes, Endocrinology and Metabolism at Imperial College London.
(iv) Director of Research for the Division of Medicine & Integrated Care at Imperial College Healthcare NHS Trust.
He completed his medical training at St Bartholomew’s Hospital Medical School, University of London. During this time he also completed an Intercalated BSc in Biochemistry (awarded First Class Honours). He then completed a PhD as a Wellcome Trust Clinical Training Fellow at Imperial College. He was then awarded a National Institute for Health Research (NIHR) Clinician Scientist Fellowship, followed by an NIHR Career Development Fellowship and a prestigious NIHR Research Professorship.
Professor Dhillo’s recent pioneering translational research has identified kisspeptin as a diagnostic test for patients with delayed puberty and a novel therapeutic target for patients with infertility. He has also shown that NK3 receptor antagonists are a new treatment for post-menopausal flushing.
He was been awarded the Royal College of Physicians Goulstonian Lectureship and the Society for Endocrinology Medal for this work. In 2024 he was Elected as a Fellow of the Academy of Medical Sciences
Juan Carlos Izpisua Belmonte, Founding Scientist and Director, San Diego Institute of Science. During life’s early stages cells display high levels of plasticity, regeneration and resilience against stress, dysfunction and injury, which are key features of human health. Dr. Juan Carlos Izpisua Belmonte, previously the Roger Guillemin Chair and Professor at the Salk Institute, has contributed towards understanding the molecular basis underlying embryogenesis and early postnatal life, as well as gained insights into how to program and rejuvenate adult and diseased cells. He is developing technologies to program cells to states similar to those observed in the early, healthy stages of life, with the objective of developing universal health therapeutics to overcome human disease and aging.
